AVANIR Pharmaceuticals Completes Phase II/III Clinical Trial of Neurodex for Emotional Lability
Neurodex is a patented, orally administered combination of dextromethorphan (DM) and an enzyme inhibitor that sustains elevated levels of DM in the human body. Results of a pilot study showed that the combination of DM, known to be an NMDA receptor antagonist, and an enzyme inhibitor resulted in higher and prolonged dextromethorphan blood levels (Clinical Pharmacology & Therapeutics, 1992; 51:647-55). Patients in the Phase II/III clinical trial were treated orally twice a day, on a twelve-hour dosing schedule.
"While dextromethorphan is considered to be neuroprotective, the therapeutic dilemma has been that its rapid metabolism requires extremely high doses to attain optimum therapeutic benefit," said AVANIR President and Chief Executive Officer Gerald J. Yakatan, Ph.D. "We believe Neurodex allows for improved delivery by increasing blood levels for an extended timeframe with small doses. Side effects of Neurodex may be fewer than with high doses of dextromethorphan alone."
ALS involves loss of upper motor neurons in the brain, which control lower motor neurons. The term pseudobulbar palsy is used to describe uncontrolled activity of the lower motor neurons of the bulbar (brainstem) region and is a phenomenon that seems to cause laughing and crying not necessarily associated with emotions. The loss of the upper motor neurons also results in loss of control of these physical manifestations of emotion. Episodes of uncontrolled laughing and crying can be embarrassing and even frightening to patients and their caregivers.
To determine suitability for inclusion in the trial, patients were assessed for pseudobulbar affect by clinical observation and a survey called the CNS Lability Scale (CNS-LS). The CNS-LS is a validated survey that measures frequency and severity of emotional lability-related episodes. The double-blind, controlled, multi-center clinical trial studied three patient groups consisting of patients taking Neurodex, patients taking dextromethorphan alone, and patients taking the enzyme inhibitor alone. Endpoints of the study include a comparison to baseline of average CNS-LS scores between the Neurodex and other treatment groups and comparison of the number of emotional lability episodes. The Phase II/III trial was conducted at eighteen study sites in the U.S. including Baylor College of Medicine, the University of Wisconsin at Madison, the University of California at San Francisco, the University of Miami, Columbia-Presbyterian Medical Center, Penn Neurological Institute, Northwestern Medical School and Massachusetts General Hospital.
"We anticipate obtaining final data and releasing the results of this study in July," continued Dr. Yakatan. "If successful, we plan to initiate a pivotal Phase III clinical trial with MS patients. An open-label safety study will follow the MS trial and will include patients with symptoms of emotional lability occurring in stroke, Alzheimer's disease, ALS or MS."
AVANIR has the exclusive license to develop, manufacture and market Neurodex for four potential indications: emotional lability, neuropathic pain, chronic cough and weaning drug-dependent patients from narcotics and anti-depressants. AVANIR intends to initiate a Phase II clinical trial examining Neurodex in the treatment of neuropathic pain later this year. Neurodex is protected by six issued U.S. patents.
AVANIR Pharmaceuticals, based in San Diego, is a biopharmaceutical drug discovery and development company with an FDA-approved product. AVANIR is engaged in research, discovery, development and licensing of innovative drug products and, through its subsidiary Xenerex Biosciences, antibody generation services. The Company's website is http://www.avanir.com .
AVANIR press releases and presentations, including any forward-looking statements contained therein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words as "estimate," "anticipate," "intend," "plan" or "expect." Research findings are not always supportable by evidence obtained from subsequent clinical trials and the Company can make no assurances that the Neurodex clinical trials will yield positive results. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.
For further information, please contact: General Information, Gregg Sloate, +1-310-407-6547, email@example.com, or Analyst/Investor, Tricia Ross, +1-310-407-6540, firstname.lastname@example.org, or Media, Tim Grace, +1-312-640-6667, email@example.com, all of FRB|Weber Shandwick, for AVANIR Pharmaceuticals; or Patrice Saxon, Investor Relations of AVANIR Pharmaceuticals, +1-858-622-5202, firstname.lastname@example.org.
SOURCE AVANIR Pharmaceuticals
general information, Gregg Sloate, +1-310-407-6547,
email@example.com, or investors, Tricia Ross, +1-310-407-6540,
firstname.lastname@example.org, or media, Tim Grace, +1-312-640-6667,
email@example.com, all of FRB|Weber Shandwick, for AVANIR
Pharmaceuticals; or Patrice Saxon, Investor Relations of AVANIR
Pharmaceuticals, +1-858-622-5202, firstname.lastname@example.org
/Company News On-Call: http://www.prnewswire.com/comp/509050.html
Copyright (C) 2002 PR Newswire. All rights reserved.